Anti-SLC22A3 antibody

Cat.#: 176588

Size:

Special Price 241.9 USD

Availability: In Stock
- +

Add to cart to get an online quotation

Product Information

  • Product Name
    Anti-SLC22A3 antibody
  • Documents
  • Description
    Rabbit monoclonal antibody to SLC22A3
  • Tested applications
    WB, IHC-P, FC
  • Species reactivity
    Human
  • Alternative names
    EMT antibody; EMTH antibody; OCT3 antibody
  • Isotype
    Rabbit IgG
  • Preparation
    This antigen of this antibody was recombinant protein within human slc22a3 aa 300-450.
  • Clonality
    Monoclonal
  • Formulation
    Liquid, 1*TBS (pH7.4), 0.05% BSA, 40% Glycerol. Preservative: 0.05% Sodium Azide.
  • Storage instructions
    Store at +4℃ after thawing. Aliquot store at -20℃. Avoid repeated freeze / thaw cycles.
  • Applications

    WB:1:1000-1:5,000

    IHC-P:1:50-1:200

    FC:1:50-1:100

  • Validations

    Fig1:; Western blot analysis of SLC22A3 on human placenta tissue lysates. Proteins were transferred to a PVDF membrane and blocked with 5% BSA in PBS for 1 hour at room temperature. The primary antibody ( 1/2000) was used in 5% BSA at room temperature for 2 hours. Goat Anti-Rabbit IgG - HRP Secondary Antibody (HA1001) at 1:5,000 dilution was used for 1 hour at room temperature.

    Fig1:; Western blot analysis of SLC22A3 on human placenta tissue lysates. Proteins were transferred to a PVDF membrane and blocked with 5% BSA in PBS for 1 hour at room temperature. The primary antibody ( 1/2000) was used in 5% BSA at room temperature for 2 hours. Goat Anti-Rabbit IgG - HRP Secondary Antibody (HA1001) at 1:5,000 dilution was used for 1 hour at room temperature.

    Fig2:; Immunohistochemical analysis of paraffin-embedded human colon carcinoma tissue using anti-SLC22A3 antibody. The section was pre-treated using heat mediated antigen retrieval with Tris-EDTA buffer (pH 8.0-8.4) for 20 minutes.The tissues were blocked in 5% BSA for 30 minutes at room temperature, washed with ddH; 2; O and PBS, and then probed with the primary antibody ( 1/50) for 30 minutes at room temperature. The detection was performed using an HRP conjugated compact polymer system. DAB was used as the chromogen. Tissues were counterstained with hematoxylin and mounted with DPX.

    Fig2:; Immunohistochemical analysis of paraffin-embedded human colon carcinoma tissue using anti-SLC22A3 antibody. The section was pre-treated using heat mediated antigen retrieval with Tris-EDTA buffer (pH 8.0-8.4) for 20 minutes.The tissues were blocked in 5% BSA for 30 minutes at room temperature, washed with ddH; 2; O and PBS, and then probed with the primary antibody ( 1/50) for 30 minutes at room temperature. The detection was performed using an HRP conjugated compact polymer system. DAB was used as the chromogen. Tissues were counterstained with hematoxylin and mounted with DPX.

    Fig3:; Flow cytometric analysis of SLC22A3 was done on A549 cells. The cells were fixed, permeabilized and stained with the primary antibody ( 1/50) (red). After incubation of the primary antibody at room temperature for an hour, the cells were stained with a Alexa Fluor 488-conjugated Goat anti-Rabbit IgG Secondary antibody at 1/1000 dilution for 30 minutes.Unlabelled sample was used as a control (cells without incubation with primary antibody; black).

    Fig3:; Flow cytometric analysis of SLC22A3 was done on A549 cells. The cells were fixed, permeabilized and stained with the primary antibody ( 1/50) (red). After incubation of the primary antibody at room temperature for an hour, the cells were stained with a Alexa Fluor 488-conjugated Goat anti-Rabbit IgG Secondary antibody at 1/1000 dilution for 30 minutes.Unlabelled sample was used as a control (cells without incubation with primary antibody; black).

  • Background
  • References
    • Fu L. et. al. RNA editing of SLC22A3 drives early tumor invasion and metastasis in familial esophageal cancer. Proc Natl Acad Sci U S A. 2017 Jun 6;114(23):E4631-E4640.
    • Hsu CM. et. al. Upregulated SLC22A3 has a potential for improving survival of patients with head and neck squamous cell carcinoma receiving cisplatin treatment. Oncotarget. 2017 Sep 4;8(43):74348-74358.

Please note: All products are "FOR RESEARCH USE ONLY AND ARE NOT INTENDED FOR DIAGNOSTIC OR THERAPEUTIC USE"